What is Milestone Scientific's share price today?
Milestone Scientific (MLSS) share price today is $0.31 as of November 6, 2026 at 10:10 PM IST. The stock touched a day high of $0.32 and a day low of $0.31.What exchange does Milestone Scientific stock trade on, and under what ticker symbol?
Milestone Scientific stock trades on AMEX under the ticker symbol MLSS.What is Milestone Scientific's market capitalization?
Milestone Scientific's market capitalization is $29.81M as of November 6, 2026 at 10:10 PM IST.What is Milestone Scientific's price-to-earnings (P/E) ratio?
Milestone Scientific's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.What is Milestone Scientific's price-to-book (P/B) ratio?
Milestone Scientific's price-to-book (P/B) ratio is 8.41 as of November 6, 2026.Can Indian investors buy Milestone Scientific shares?
Yes, You can buy Milestone Scientific shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Milestone Scientific shares from India?
Indian investors can buy Milestone Scientific shares in three steps: 1. Search Milestone Scientific on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Milestone Scientific shares for Indian investors?
Since Milestone Scientific trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Milestone Scientific shares via Tickertape?
Indian investors can start investing in Milestone Scientific (MLSS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 31.746 shares at the current price of $0.31.
Key Metrics
Key Metrics
Close price divided by the earnings per share for the trailing twelve months
Close price divided by the book value per share at the end of the most recent quarter
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
Net profit divided by the total revenue for the most recent financial year
Annual dividend per share for the trailing twelve months divided by the close price
Based on 2 analysts reports
Price Upside
+317.92%
Earnings Growth
+33.33%
Rev. Growth
+11.14%
Company Profile
Company Profile
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
All values in $
All values in $
Revenue Forecast
Revenue Forecast
The next fiscal year's mean estimate implies 11.14% growth, versus a trailing 3-year CAGR of 0.63%.
All values in $ Million
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
All values in $
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.24 | 1.85 | 2.51 | 2.01 | 2.23 | 2.32 | 2.36 | 2.05 | 2.16 | 2.84 |
| Gross Profit | 1.67 | 1.41 | 1.83 | 1.51 | 1.64 | 1.61 | 1.62 | 1.48 | 1.54 | 1.91 |
| Net Income | -1.44 | 0.22 | -1.46 | -2.03 | -1.99 | -1.48 | -1.15 | -1.09 | -0.83 | -1.05 |
| Net Profit Margin | -64.05% | 12.06% | -58.12% | -101.09% | -89.34% | -63.83% | -48.89% | -52.99% | -38.84% | -37.28% |
Peers
Peers & Comparison
Peers & Comparison
HealthcareMedical Instruments & Supplies
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Milestone Scientific | - | 8.41 | 0 |
| Abbott Laboratories | 42.94 | 3.70 | 1.56 |
| Intuitive Surgical Inc | 58.29 | 9.74 | 2.04 |
The 12-month consensus target implies 317.92% growth, versus a trailing 3-year CAGR of -28.84%.